RiboBio

Guangzhou, China Founded: 2004 • Age: 22 yrs
Developer of oligonucleotides

About RiboBio

RiboBio is a Healthcare company based in Guangzhou (China) founded in 2004. Developer of oligonucleotides. RiboBio has raised $40 million across 1 funding round from investors including SANY Group and Panlin Capital. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its competitors include Sino Biological and Sangon Biotech; 2 of its 2 listed competitors have raised funding.

Company details

Founded in 2004 and based in Guangzhou, China, oligonucleotides are developed by RiboBio within the biotechnology sector. A GMP-approved manufacturing facility is operated for production, alongside process development services. RD offerings encompass RNAimiRNA functional studies, high-throughput screens for RNAi and small molecules, and microarray analysis for mRNA and miRNA. A proprietary solid-phase synthesis process for RNA oligonucleotides has been established.

  • Headquarters Guangzhou, China
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website ribobio.com
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $40M (USD)

    in 1 rounds

  • Latest Funding Round
    $40M (USD), Series E

    Jul 2022

  • Investors
    SANY Group

    & 1 more

Funding Insights of RiboBio

RiboBio has successfully raised a total of $40M through 1 strategic funding round. The most recent funding activity was a Series E round of $40 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $40M
  • Total Rounds 1
  • Last Round Series E β€” $40M
  • First Round $40M

    (Jul 2022)

  • Investors Count 2

All 1 funding rounds of RiboBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2022$40MSeries E–Panlin Capital
Valuation history

2 investors in total: 2 institutional.

Investors in RiboBio

RiboBio has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include SANY Group and Panlin Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
panlincap.com
Manufacturer of construction & mining equipment, port, and oil drilling machinery
1989sanyglobal.comChangsha, China
Premium access

Investor details for RiboBio

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of RiboBio

2 dated milestones of RiboBio across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded RiboBio is founded.
  2. Funding First funding round of $40.0M.

Competitors of RiboBio

RiboBio has 2 listed competitors in our database, 2 of them funded. They include Sino Biological and Sangon Biotech.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
sinobiological.com2007Beijing, China$29.41M
Reagents and kits are provided for clinical research applications.
sangon.com2003Shanghai, China$300M
Research services, reagents, and kits for biotech applications are provided.
Premium access

Detailed competitors of RiboBio

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of RiboBio

Websites that share an audience with RiboBio (ribobio.com).

Similar websites

Websites whose visitors overlap most with RiboBio. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
uptbio.com
uptbio.com
100%
#9,568,018–
shbiochip.com
78%
View details
sangon.com
77%
226.9K#101,937View details
beyotime.com
beyotime.com
77%
–
thermofisher.cn
thermofisher.cn
38%
#53,435–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ribobio

Premium access

Complete news archive for RiboBio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about RiboBio

RiboBio was founded in 2004 and raised its 1st funding round 18 years after it was founded.

RiboBio is headquartered in Guangzhou, China. It is registered at Guangzhou, Guangdong, China.

RiboBio is a funded company, having raised a total of $40M across 1 funding round to date. The company's 1st funding round was a Series E of $40M, raised on Jul 2022.

Founded in 2004 and based in Guangzhou, China, oligonucleotides are developed by RiboBio within the biotechnology sector. A GMP-approved manufacturing facility is operated for production, alongside process development services. RD offerings encompass RNAimiRNA functional studies, high-throughput screens for RNAi and small molecules, and microarray analysis for mRNA and miRNA. A proprietary solid-phase synthesis process for RNA oligonucleotides has been established.

RiboBio's top competitors include Sino Biological and Sangon Biotech.

RiboBio has 2 investors. Key investors include SANY Group, and Panlin Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available